Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index

Choi, Yun‐Shik; Oh, Do‐Youn; Kim, Tae-Yong; Lee, Kyung-Hun; Han, Sae‐Won; Im, Seock‐Ah; Kim, Tae-You; Bang, Yung‐Jue

doi:10.1371/journal.pone.0139749

Cited by 197 publications

(174 citation statements)

References 28 publications

Supporting

Mentioning

162

Contrasting

Unclassified

Order By: Relevance

“…Our cut-off values of L3 SMI were much lower than those reported by Prado et al [9] (52.4 cm 2 /m 2 for men and 38.5 cm 2 /m 2 for women). However, the cut-offs in our study are comparable to the Korean cut-offs reported by Choi et al [21] (42.2 cm 2 /m 2 for men and 33.9 cm 2 /m 2 for women). These differences seem to be due to the physical differences between Westerners and Asians.…”

Section: Discussionsupporting

confidence: 87%

The Impact of Skeletal Muscle Depletion on Head and Neck Squamous Cell Carcinoma

Nishikawa

Hanai

Suzuki

et al. 2018

ORL

View full text Add to dashboard Cite

Background: Skeletal muscle depletion and sarcopenia have been reported as poor prognostic factors for several types of cancer. The aim of this study was to investigate the prognostic impact of skeletal muscle depletion and sarcopenia on the outcomes in head and neck cancer patients. Methods: Patients with head and neck squamous cell carcinoma (HNSCC) treated from January 2013 to June 2014 were included in this study. The pretreatment cross-sectional area of skeletal muscle at the third lumbar vertebra (L3) was measured by computed tomography image analysis using the ImageJ software. L3 skeletal muscle index (SMI) and fat-free mass (FFM) were calculated. Results: Eighty-five patients with HNSCC were included. The cut-off value of sarcopenia was set at SMI <46.7 cm²/m² (males) and 30.3 cm²/m² (females). The cut-off value of FFM was set at 42.3 kg (males) and 30.6 kg (females). Patients with a low SMI (sarcopenia) and low FFM had a significantly poorer prognosis than others, especially those who received definitive radiotherapy. Sarcopenia and low FFM are independent factors for poor prognosis in patients with HNSCC. Conclusion: The skeletal muscle area at L3 should be calculated when considering treatment options for head and neck cancer.

show abstract

Section: Discussionsupporting

confidence: 87%

The Impact of Skeletal Muscle Depletion on Head and Neck Squamous Cell Carcinoma

Nishikawa

Hanai

Suzuki

et al. 2018

ORL

View full text Add to dashboard Cite

show abstract

“…However, as aforementioned, few reports have addressed this important clinical question in patients with unresectable APC who are receiving systemic chemotherapy (24,25). The present study was, therefore, conducted.…”

Section: Discussionmentioning

confidence: 95%

“…However, to the best of our knowledge, there are few reports regarding the impact of DSMM on survival in patients with unresectable APC undergoing systemic chemotherapy (24,25). Therefore, it is imperative to address these issues.…”

Section: Effect Of Pretreatment Psoas Muscle Mass On Survival For Patmentioning

confidence: 99%

Effect of pretreatment psoas muscle mass on survival for patients with unresectable pancreatic cancer undergoing systemic chemotherapy

et al. 2017

View full text Add to dashboard Cite

Abstract. To the best of our knowledge, there are few previous studies that have investigated the effect of decreased skeletal muscle mass (DSMM) on survival in patients with unresectable advanced pancreatic cancer (APC) who are undergoing systemic chemotherapy. Thus, the present study aimed to investigate the impact of DSMM, as determined by the psoas muscle index (PMI) following computed tomography and prior to systemic chemotherapy, on the outcomes of patients with unresectable APC (n=61). The primary endpoint used was the overall survival (OS) rate. The OS rates in the PMI-High group (exceeds the median PMI value in each gender) were retrospectively compared with those in the PMI-Low group (below the median PMI value in each gender), and factors associated with OS were investigated using univariate and multivariate analyses. The study cohort included 31 male and 30 female patients with a median age of 72 years, 13 of whom were stage IVA, and 48 were stage IVB. ). The proportion of patients with performance status 0 in the PMI-High group was significantly high, compared with that in the PMI-Low group [83.3% (25/30) vs. 58.1% (18/31); P=0.0486]. Body mass index in the PMI-High group was significantly higher compared with that in the PMI-Low group (P=0.0154). The 1-year cumulative survival rate was 43.3% in the PMI-High group and 12.9% in the PMI-Low group (P=0.0027). Following multivariate analysis, PMI (P=0.0036), prothrombin time (P=0.0044) and carbohydrate antigen 19-9 (P= 0.0451) were identified to be significant predictors of OS. In conclusion, DSMM, as determined by the PMI, could be a significant predictor of prognosis in patients with unresectable APC who are receiving systemic chemotherapy.

show abstract

“…83–85 More recently, it has been linked to higher chemotherapy toxicity rates and hospitalizations during treatment for patients with metastatic breast and pancreatic cancer. 86,87 This treatment-related frailty has been associated with worse physical performance measures over the course of treatment and higher risk for falls in this patient population. Exercise-based interventions may offset some of the impact of this decline.…”

Section: Methodsmentioning

confidence: 99%

The Older Adult With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: Knowledge Gaps and Future Direction in Assessment and Treatment

Maggiore

Zumsteg

BrintzenhofeSzoc

et al. 2017

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Older adults with squamous cell carcinomas of the head and neck (HNSCC) pose unique treatment and supportive care challenges to oncologists and other cancer care providers. The majority of patients with HNSCC present with locoregionally advanced (LA) disease, for which combined modality treatment integrating chemotherapy and radiation therapy is often necessary to maximize tumor control. However, applying these approaches to an older population with concomitant comorbidities and higher risk for functional impairments remains challenging, and is exacerbated by the paucity of studies involving older adults. The purpose of this paper is to identify knowledge gaps in the evaluation and management of older adults with HNSCC and their caregivers, particularly those undergoing concurrent chemoradiation, through a review of the literature conducted by clinicians, researchers, and patient advocates. The findings highlight the importance of a geriatric assessment and the therapeutic paradigms and challenges relevant to this population. Furthermore, we identify the need for additional research and interventions related to key supportive care issues that arise during and after treatment in older adults with LA-HNSCC. Based on our findings, we prioritized these issues to guide future patient-oriented research endeavors to address these knowledge gaps and thus better serve this growing patient population.

show abstract

Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index

Cited by 197 publications

References 28 publications

The Impact of Skeletal Muscle Depletion on Head and Neck Squamous Cell Carcinoma

The Impact of Skeletal Muscle Depletion on Head and Neck Squamous Cell Carcinoma

Effect of pretreatment psoas muscle mass on survival for patients with unresectable pancreatic cancer undergoing systemic chemotherapy

The Older Adult With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: Knowledge Gaps and Future Direction in Assessment and Treatment

Contact Info

Product

Resources

About